Health And Medicine
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read MoreFeb 22, 2022
-
Pandemic leads to broader use of monoclonal antibodies
Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19. Read MoreFeb 17, 2022
-
Watch: ‘Black Excellence in Research and the Future of Diversity in Academia’ virtual event
In recognition of Black History Month, the School of Medicine Basic Sciences’ monthly virtual Lab-to-Table Conversation will celebrate Black excellence in research and discuss the future of diversity in academia. The event will take place on Tuesday, Feb. 22, from noon to 1 p.m. CT. Read MoreFeb 16, 2022
-
Richard Sando awarded 2022 Sloan Research Fellowship in neuroscience
Richard Sando, assistant professor of pharmacology, has been selected to receive a 2022 Sloan Research Fellowship, one of the most competitive and prestigious awards available to early-career researchers. Read MoreFeb 15, 2022
-
Predicting brain cancer outcome
Red blood cell distribution width has prognostic value for many diseases, but it was not associated with overall survival in patients with glioblastoma, Vanderbilt researchers found. Read MoreFeb 15, 2022
-
Research Snapshot: Vanderbilt researchers discover new spontaneous signaling pathway in the brain
Ege Kavalali and Heidi Hamm collaborated to discover a signaling pathway for how spontaneous release of neurotransmitters can be selectively regulated without disrupting evoked action potentials. Read MoreFeb 14, 2022
-
New insights into hypothalamic obesity
A common Type 2 diabetes treatment being tested for hypothalamic obesity had unexpected results on weight loss and total energy expenditure, Vanderbilt researchers report. Read MoreFeb 10, 2022
-
Diverticulitis surgery: guidelines needed
Surgical removal of the colon for recurrent diverticulosis varies by geographic region and is associated with surgeon and hospital factors; stronger national guidelines are needed, Vanderbilt researchers report. Read MoreFeb 10, 2022
-
Gene variants increase risk of kidney failure in Black veterans with COVID-19: study
Gene variants increased the risk of acute kidney injury and death in veterans of African ancestry who were hospitalized with COVID-19, possibly explaining some health disparities associated with COVID-19. Read MoreFeb 10, 2022
-
Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization
Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%. Read MoreFeb 9, 2022
-
Ege Kavalali to lead pharmacology department in School of Medicine Basic Sciences
Ege T. Kavalali, William Stokes Professor of Experimental Therapeutics, has been named chair of the Department of Pharmacology in the Vanderbilt University School of Medicine Basic Sciences. Read MoreFeb 4, 2022
-
VUMC study raises hope for improving treatment of kidney disease
Vanderbilt research has revealed an important mechanism in the kidney by which a cell surface receptor known as DDR1 fans the flames of inflammation and fibrosis that ultimately lead to kidney failure. Read MoreFeb 2, 2022
-
Impact of digital health interventions
Vanderbilt researchers test and recommend statistical approaches to study the association between engagement with digital health interventions and clinical outcomes. Read MoreJan 31, 2022
-
Impaired neutrophils in autoimmunity
Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity. Read MoreJan 27, 2022
-
Seven Vanderbilt faculty elected as AAAS fellows in 2021
Provost and Vice Chancellor for Academic Affairs C. Cybele Raver joins six others at Vanderbilt as 2021 fellows of the American Association for the Advancement of Science, the world’s largest general scientific society. Read MoreJan 26, 2022
-
Inaugural Vanderbilt Critical Psychiatry Conference spurred by student’s research interest into depressive behaviors
When Joseph Sexton’s friend died by suicide in high school, Sexton channeled his grief into a research quest to better understand depressive behaviors. The Georgia native started studying the systems and molecular neuroscience behind mood. By his senior year of high school, he was doing research at Georgia… Read MoreJan 21, 2022
-
Omicron evades some but not all monoclonal antibodies: study
A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States. Read MoreJan 20, 2022
-
Lopez lab develops computational tools to further understanding of complex biological systems
By Aaron Conley Systems biology and the Lopez lab The history of hermeneutics started with Aristotle—parts comprise the whole. To understand the whole, we need to understand the parts. And to understand the parts, we need to understand them in the context of the whole. Carlos F. Lopez, associate… Read MoreJan 20, 2022
-
Watch: ‘The Science of Flavor’ conversation explores how flavor science impacts the restaurant industry
Join taste experts, scientists and a Nashville chef to learn about the science behind flavor in a virtual event on Monday, Jan. 31, at noon CT. Read MoreJan 18, 2022
-
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy
A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. Read MoreJan 14, 2022